The Thomsen-Friedenreich (TF) antigen is a key target for the development of anticancer vaccines. and this ongoing challenge remains relevant due to the poor immunogenicity of the TF antigen. To overcome this challenge. we adopted a bivalent conjugate design which introduced both the TF antigen and the Thomsen-nouveau (Tn) antigen onto the immunologically relevant polysaccharide A1 (P... https://pyrodresoners.shop/product-category/helicopters/